Upcoming Webinar:'COLLECTIVE FORCE: India Inc. unites to tackle the second wave of COVID-19' on June 23, 11 am. Register Now!

Nykaa gets Rs 100-crore funding boost from Steadview Capital

The funding announcement came a few hours after the company suspended operations, citing the lockdown.

April 01, 2020 / 01:42 PM IST

Beauty and fashion retailer Nykaa has raised Rs 100 crore from existing investor Steadview Capital, a UK-based hedge fund, the company said early on April 1, hours after it suspended operations across the country.

The round values Nykaa at $1.2 billion (Rs 9,200 crore), nearly double the $750 million (Rs 5,000 crore) it was valued at last year when private equity firm TPG Growth invested Rs 100 crore.

Moneycontrol first reported on March 9 that Nykaa was targeting a valuation of $1.2 billion in a fundraise this year, and is the latest addition to India’s coveted list of unicorns, or firms valued at over a billion dollars.

Avendus Capital was the financial adviser to the deal.

Steadview’s fund push comes at a time when the Mumbai-based retailer has suspended operations amid a 21-day countrywide lockdown to check the spread of coronavirus even though infections continue to inch up.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

On April 1, the eighth day of the lockdown, the number of confirmed cases stood at 1,397. Thirty-five people have died of COVID-19, the health ministry has said, referring to the respiratory disease caused by the virus.

A few hours earlier, Nykaa shut down its offline stores, corporate offices and warehouses. It would not be able to make payments to vendors and partners in time, the company said, citing disruptions in cash flow due to the lockdown.

“We deeply value the trust and support of our investors, customers and brand partners who have been instrumental to our success. In the midst of this unprecedented global crisis we are working to ensure all our stakeholders are well served and that Nykaa emerges as a leading retail player in the industry,” founder and CEO Falguni Nayar said in a statement.
M. Sriram
first published: Apr 1, 2020 12:30 pm

stay updated

Get Daily News on your Browser